Suppr超能文献

头孢哌酮-舒巴坦的体外活性:新加坡的经验

In vitro activity of cefoperazone-sulbactam: Singapore experience.

作者信息

Kumarasinghe G, Chow C, Chiu C, Cheong Y M

机构信息

Division of Microbiology, National University Hospital, Kent Ridge, Singapore.

出版信息

Southeast Asian J Trop Med Public Health. 1996 Dec;27(4):734-7.

PMID:9253876
Abstract

In vitro activity of commonly used antimicrobial agents against consecutively isolated 521 strains of Gram negative bacilli causing serious infections in the National University Hospital, Singapore were tested in parallel with cefoperazone-sulbactam combination. With the combination complete resistance of 2% and intermediate resistance of 5% were noted among the 521 strains tested. Resistance to imipenem was low (5%) but resistance against other antimicrobial agents varied from 12% (amikacin) to 80% (ampicillin). In vitro data demonstrated a possible future role for cefoperazone-sulbactam in the treatment of sepsis caused by Gram negative bacilli in our hospital.

摘要

对新加坡国立大学医院连续分离出的521株引起严重感染的革兰氏阴性杆菌,测试了常用抗菌药物的体外活性,并与头孢哌酮-舒巴坦联合用药进行了平行试验。在测试的521株菌株中,该联合用药的完全耐药率为2%,中介耐药率为5%。对亚胺培南的耐药率较低(5%),但对其他抗菌药物的耐药率从12%(阿米卡星)到80%(氨苄西林)不等。体外数据表明,头孢哌酮-舒巴坦在我院治疗革兰氏阴性杆菌引起的败血症方面可能具有未来应用价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验